Positive Phase 3 Results Reported for Olorofim in Invasive Aspergillosis Treatment

Shionogi and F2G have announced positive Phase 3 OASIS study results for oral olorofim, demonstrating its non-inferiority to standard of care for adult patients with invasive aspergillosis. The novel antifungal showed comparable Day 42 all-cause mortality (23.8% vs. 24.3%) and fewer adverse events in patients whose infection was refractory to or unsuitable for azole therapy. These findings were presented at IDWeek 2026.